A composite outcome for neonatal cardiac surgery research

Ryan J. Butts, MD,a Mark A. Scheurer, MD,a Sinai C. Zyblewski, MD,a Amy E. Wahlquist, MS,b Paul J. Nietert, PhD,b Scott M. Bradley, MD,c Andrew M. Atz, MD,a and Eric M. Graham, MDa

Objectives: The objective of this study was to determine whether a composite outcome, derived of objective signs of inadequate cardiac output, would be associated with other important measures of outcomes and therefore be an appropriate end point for clinical trials in neonatal cardiac surgery.

Methods: Neonates (n = 76) undergoing cardiac operations requiring cardiopulmonary bypass were prospectively enrolled. Patients were defined to have met the composite outcome if they had any of the following events before hospital discharge: death, the use of mechanical circulatory support, cardiac arrest requiring chest compressions, hepatic injury (2 times the upper limit of normal for aspartate aminotransferase or alanine aminotransferase), renal injury (creatinine >1.5 mg/dL), or lactic acidosis (an increasing lactate >5 mmol/L in the postoperative period). Associations between the composite outcome and the duration of mechanical ventilation, intensive care unit stay, hospital stay, and total hospital charges were determined.

Results: The median age at the time of surgery was 7 days, and the median weight was 3.2 kg. The composite outcome was met in 39% of patients (30/76). Patients who met the composite outcome compared with those who did not had a longer duration of mechanical ventilation (4.9 vs 2.9 days, P < .01), intensive care unit stay (8.8 vs 5.7 days, P < .01), hospital stay (23 vs 12 days, P < .01), and increased hospital charges ($258,000 vs $170,000, P < .01). In linear regression analysis, controlling for surgical complexity, these differences remained significant (R² = 0.29-0.42, P < .01).

Conclusions: The composite outcome is highly associated with important early operative outcomes and may serve as a useful end point for future clinical research in neonates undergoing cardiac operations. (J Thorac Cardiovasc Surg 2014;147:428-33)
scientific community. The advantages supporting the use of a composite outcome are that it increases statistical efficiency because of higher event rates, which reduces sample size requirement, cost, and time, and that it allows investigators to avoid an arbitrary choice between several important outcomes. These advantages have resulted in the widespread use of composite outcomes in clinical trials, including pediatric heart disease. The objective of this study was to use a standardized composite outcome for neonatal cardiac surgery in a well-characterized cohort and correlate this composite outcome with other important early postoperative outcomes.

MATERIALS AND METHODS
The study is a secondary analysis of a prospective randomized controlled trial comparing preoperative glucocorticoid therapy in 76 neonates (ClinicalTrials.gov Identifier NCT00934843). The study was approved by the Medical University of South Carolina’s Institutional Review Board, and informed written consent was obtained from the parent or legal guardian of all participants.

Composite Outcome
The individual components of the composite outcome were composed of clinical and laboratory signs of inadequate tissue oxygen delivery or circulatory collapse. Six components were chosen because each represents important early clinical outcomes, often resulting from low cardiac output, and have been associated with poor outcomes in other studies. The components include death, circulatory collapse requiring chest compressions (cardiopulmonary resuscitation [CPR]), mechanical circulatory support (extracorporeal membrane oxygenation [ECMO]), hepatic insufficiency, renal insufficiency, and lactic acidosis. Hepatic injury was defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal (normal range, AST 8-40 IU/L; hepatic injury, AST >80 IU/L; normal range, ALT 7-40 IU/L; hepatic injury, ALT >80 IU/L). Elevated AST within the first 24 postoperative hours was not considered hepatic insufficiency because of higher event rates, which reduces sample size requirement, cost, and time, and that it allows investigators to avoid an arbitrary choice between several important outcomes. These advantages have resulted in the widespread use of composite outcomes in clinical trials, including pediatric heart disease. The objective of this study was to use a standardized composite outcome for neonatal cardiac surgery in a well-characterized cohort and correlate this composite outcome with other important early postoperative outcomes.

Liver function panels were ordered as part of the study protocol on arrival to the ICU and 36 hours after arrival. Additional liver function tests were obtained as clinically indicated and analyzed for the composite outcome. Serum creatinine was measured on arrival to the ICU from the operating room and then daily for a minimum of 2 days. It was common practice during the study period to have creatinine levels checked daily while in the ICU if arterial or central venous access was present; however, this practice was not required by the study protocol. Lactate levels were obtained via arterial catheters and obtained on arrival to the ICU and at 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours postoperatively at a minimum and more often as clinically indicated.

Study Population
All inpatient neonates (aged ≤30 days) scheduled to undergo cardiac surgery involving CPB from July 2007 to July 2009 were eligible for this study. Exclusion criteria included prematurity (defined as ≤36 weeks gestational age at the time of surgery), previous treatment with or contraindication to steroid therapy, or preoperative use of mechanical circulatory support or active resuscitation at the time of proposed randomization. Patients were randomly assigned to preoperative placebo and intraoperative methylprednisolone (1 dose) or preoperative and intraoperative methylprednisolone (2 doses). Details on the study population have been reported.

Data Analysis
The characteristics of the patients who met the composite outcome were compared with those who did not with respect to surgical complexity by the Risk Adjustment for Congenital Heart Surgery 1 (RACHS-1) classification, age at surgery, weight at surgery, length of CPB, use of aprotinin, or delayed sternal closure. Continuous data were compared using the Wilcoxon rank-sum test; categorical data were analyzed with the chi-square test. Patients who met the composite outcome were compared with those who did not with respect to duration of postoperative mechanical ventilation, ICU stay, hospital stay, and hospital charges using the Wilcoxon rank-sum test.

To explore the associations between meeting more than 1 criteria or meeting the more clinically significant criteria and outcomes, patients were further separated into 3 groups based on the number of composite outcome criteria met: none, only 1, and more than 1. Patients were further classified as meeting 1 of the criteria (CPR, ECMO, death), laboratory criteria only (hepatic or renal injury, lactic acidosis), or no criteria. Comparisons were made between groups using the Kruskal–Wallis test for nonparametric data. Because patients who die in the hospital often have more extensive resource use, sensitivity analyses were performed to determine whether findings changed significantly when those patients (n = 2) were excluded.

To perform linear regression analysis, postoperative outcomes were log-transformed to create parametric distribution. Surgical complexity was controlled in the regressions analysis by dichotomizing patients with a RACHS-1 class of 5 or 6 and patients with a RACHS-1 class of 2 to 4. An alpha level less than 0.05 was considered statistically significant.

RESULTS
All 76 patients had complete records for review and were included in the analysis. Patient demographics, cardiac diagnoses, surgical procedures performed, and intraoperative parameters have been described. Median gestational age was 39 weeks (interquartile range [IQR], 38-39.3). Median weight at surgery was 3.2 kg (IQR, 2.9-3.5). Diagnostic classification based on RACHS-1 class is shown in Table 1. Of the 76 patients, 30 (39%) met the composite outcome. There were 2 deaths before hospital discharge, resulting in
a 97% hospital survival. ECMO was used postoperatively in 4 patients (for an inability to wean from CPB in 2 and for low cardiac output in 2); all survived. Cardiac arrest requiring chest compressions occurred in 3 patients, and all were successfully resuscitated without the use of mechanical support. A serum lactate that increased in the postoperative period and that was greater than 5 mmol/L was present in 14 patients. Hepatic injury occurred in 17 patients, and 4 patients had renal injury. More than 1 criterion for the composite outcome was present in 10 patients.

Preoperative and intraoperative characteristics of those who met the composite outcome compared with those who did not are shown in Table 2. The group that met the composite outcome had a higher RACHS-1 categorization than the group that did not meet the composite outcome. The groups were otherwise similar with respect to age and weight at time of surgery, CPB time, use of aprotinin, corrective versus palliative surgery, and use of delayed sternal closure. Between steroid treatment groups, there were no differences in meeting the composite outcome (49% 1 dose vs 51% 2 doses, \( P = .8 \)).

Patients who met the composite outcome had longer median hospital stay by 11 days, ICU stay by 3.1 days, mechanical ventilation by 2 days, and higher median hospital charges by $88,000 compared with those who did not meet the composite outcome (Table 3). Linear regression analysis showed that after controlling for RACHS-1 classification, patients who met the composite outcome had an 83% longer hospital stay (95% confidence interval [CI], 42-137; \( R^2 = 0.42; P < .01 \)), 88% longer ICU stay (95% CI, 42-150; \( R^2 = 0.34; P < .01 \)), 105% longer time on mechanical ventilation (95% CI, 42-197; \( R^2 = 0.29; P < .01 \)), and 52% higher total hospital charges (95% CI, 25-84; \( R^2 = 0.33; P < .01 \)).

Patients who met more than 1 criteria for the composite outcome had longer median hospital stay by 20.5 days, ICU stay by 11.6 days, mechanical ventilation by 7.8 days, and higher median hospital charges by $193,000, compared with those who met 1 criteria (Table 4). Patients who met 1 criteria had longer hospital stay, ICU stay, and mechanical ventilation, and higher hospital charges compared with those who met no criteria (Table 4 and Figure 1).

Patients who met 1 of the clinical criteria of death, ECMO, or CPR had longer median hospital stay, ICU stay, and mechanical ventilation, as well as higher median hospital charges, compared with those who met only laboratory criteria (Table 5 and Figure 2). These differences persisted when comparing patients who met the laboratory criteria only with those who met no criteria (Table 5 and Figure 2). After excluding the 2 patients who died, all associations shown in Tables 3, 4, and 5 remained relatively unchanged and statistically significant (\( P < .01 \)).

**DISCUSSION**

The results of this study demonstrate that the composite outcome is both reasonably prevalent and highly associated with important early operative outcomes and thus may serve as a useful end point for future clinical research in neonates undergoing cardiac operations with CPB. The components of the composite outcome were selected on the basis of

**TABLE 1. Diagnostic classification**

<table>
<thead>
<tr>
<th>RACHS-1 category</th>
<th>N = 76</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>6 (8%)</td>
</tr>
<tr>
<td>3</td>
<td>25 (33%)</td>
</tr>
<tr>
<td>4</td>
<td>25 (33%)</td>
</tr>
<tr>
<td>5</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>6</td>
<td>19 (25%)</td>
</tr>
</tbody>
</table>

**Corrective surgery** 43 (57%)

*CHD, Risk-Adjusted Classification for Congenital Heart Surgery. 

**TABLE 2. Patient characteristics and composite outcome**

<table>
<thead>
<tr>
<th>Composite outcome</th>
<th>Yes (n = 30)</th>
<th>No (n = 46)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RACHS-1 class*</td>
<td>4 (4-6)</td>
<td>3 (3-4)</td>
<td>.01</td>
</tr>
<tr>
<td>Age (d)</td>
<td>7 (5-12)</td>
<td>7 (6-8)</td>
<td>.95</td>
</tr>
<tr>
<td>Weight at surgery (kg)*</td>
<td>3.3 (2.8-3.6)</td>
<td>3.2 (2.9-3.5)</td>
<td>.89</td>
</tr>
<tr>
<td>Delayed sternal closure, n (%)</td>
<td>19 (63%)</td>
<td>19 (41%)</td>
<td>.06</td>
</tr>
<tr>
<td>CPB (min)*</td>
<td>162 (123-215)</td>
<td>155 (128-171)</td>
<td>.28</td>
</tr>
<tr>
<td>Aprotinin use, n (%)</td>
<td>17 (57%)</td>
<td>17 (37%)</td>
<td>.15</td>
</tr>
<tr>
<td>Corrective surgery, n (%)</td>
<td>16 (53%)</td>
<td>27 (59%)</td>
<td>.82</td>
</tr>
</tbody>
</table>

*Continuous data expressed in median (IQR); Wilcoxon rank-sum test performed.

**TABLE 3. Composite outcome and postoperative outcomes**

<table>
<thead>
<tr>
<th>Composite outcome</th>
<th>Yes (n = 30)</th>
<th>No (n = 46)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital stay (d)</td>
<td>23 (16-39)</td>
<td>12 (9-22)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>ICU stay (d)</td>
<td>8.8 (6.3-19)</td>
<td>5.7 (4.1-7)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Mechanical ventilation (d)</td>
<td>4.9 (3.8-12.8)</td>
<td>2.9 (1.9-3.9)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Hospital charges ($1000)</td>
<td>258 (188-403)</td>
<td>170 (137-211)</td>
<td>&lt;.01</td>
</tr>
</tbody>
</table>

Values displayed are medians (IQR). ICU, Intensive care unit.

**TABLE 4. Number of composite outcome criteria met and postoperative outcomes**

<table>
<thead>
<tr>
<th>Composite outcome</th>
<th>Yes (n = 20)</th>
<th>No (n = 46)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital stay (d)</td>
<td>41.5 (24.0-60.0)</td>
<td>21.0 (16.5-36.0)</td>
<td>12.0 (9.0-22.0)</td>
</tr>
<tr>
<td>ICU stay (d)</td>
<td>19.4 (10.8-36.0)</td>
<td>7.8 (6.1-10.3)</td>
<td>5.7 (4.1-7.0)</td>
</tr>
<tr>
<td>Mechanical ventilation (d)</td>
<td>12.4 (7.0-28.0)</td>
<td>4.6 (3.4-5.4)</td>
<td>2.9 (1.9-3.9)</td>
</tr>
<tr>
<td>Hospital charges ($1000)</td>
<td>418 (267-506)</td>
<td>225 (184-262)</td>
<td>170 (137-211)</td>
</tr>
</tbody>
</table>

Values displayed are medians (IQR). \( \geq 1 \) = patients who met \( \geq 2 \) composite outcome criteria, 1 = patients who met 1 composite outcome criteria. ICU, Intensive care unit.
previously described associations with poor short- or long-
term outcomes after congenital cardiac surgery, and as such
classify clinically significant outcomes.16,18-21

The use of a composite outcome for end points in clinical
research is done frequently in cardiovascular research and
multiple other fields of medicine.10,25,26 Composite
outcomes have the advantage of increasing the event rate,
which increases the power of a study population, as long
as the composite outcome event rate is closer to 50%

than any of the individual component event rates. The
studied composite outcome had an event rate of 39%,
which is closer to 50% than the most common individual
component, hepatic injury with a 22% event rate. Thus,
the use of this composite outcome will increase the power
of a study. The reduction in study population has the
advantages of reduced costs, ability to perform
investigations in a timely manner, and avoidance of an
arbitrary choice between several outcomes.

Despite the advantages of composite outcomes, their use
can be misleading. This may be particularly relevant when
the components of the composite outcome vary in clinical
importance. Studies demonstrate that the treatment effect
is often biggest for the less important components and
smallest for the most important component.11 This is con-
sistent with the present study in which the lower morbidity
components of the composite outcome (hepatic and renal
insufficiency and lactic acidosis) occurred more often
than any of the individual component event rates. The
studied composite outcome had an event rate of 39%,
which is closer to 50% than the most common individual
component, hepatic injury with a 22% event rate. Thus,
the use of this composite outcome will increase the power
of a study. The reduction in study population has the
advantages of reduced costs, ability to perform
investigations in a timely manner, and avoidance of an
arbitrary choice between several outcomes.

Despite the advantages of composite outcomes, their use
can be misleading. This may be particularly relevant when
the components of the composite outcome vary in clinical
importance. Studies demonstrate that the treatment effect
is often biggest for the less important components and
smallest for the most important component.11 This is con-
sistent with the present study in which the lower morbidity
components of the composite outcome (hepatic and renal
insufficiency and lactic acidosis) occurred more often
than any of the individual component event rates. The
studied composite outcome had an event rate of 39%,
which is closer to 50% than the most common individual
component, hepatic injury with a 22% event rate. Thus,
the use of this composite outcome will increase the power
of a study. The reduction in study population has the
advantages of reduced costs, ability to perform
investigations in a timely manner, and avoidance of an
arbitrary choice between several outcomes.

Despite the advantages of composite outcomes, their use
can be misleading. This may be particularly relevant when
the components of the composite outcome vary in clinical
importance. Studies demonstrate that the treatment effect
is often biggest for the less important components and
smallest for the most important component.11 This is con-
sistent with the present study in which the lower morbidity
components of the composite outcome (hepatic and renal
insufficiency and lactic acidosis) occurred more often
than any of the individual component event rates. The
studied composite outcome had an event rate of 39%,
which is closer to 50% than the most common individual
component, hepatic injury with a 22% event rate. Thus,
the use of this composite outcome will increase the power
of a study. The reduction in study population has the
advantages of reduced costs, ability to perform
investigations in a timely manner, and avoidance of an
arbitrary choice between several outcomes.

Despite the advantages of composite outcomes, their use
can be misleading. This may be particularly relevant when
the components of the composite outcome vary in clinical
importance. Studies demonstrate that the treatment effect
is often biggest for the less important components and
smallest for the most important component.11 This is con-
sistent with the present study in which the lower morbidity
components of the composite outcome (hepatic and renal
insufficiency and lactic acidosis) occurred more often
than any of the individual component event rates. The
studied composite outcome had an event rate of 39%,
which is closer to 50% than the most common individual
component, hepatic injury with a 22% event rate. Thus,
the use of this composite outcome will increase the power
of a study. The reduction in study population has the
advantages of reduced costs, ability to perform
investigations in a timely manner, and avoidance of an
arbitrary choice between several outcomes.

Despite the advantages of composite outcomes, their use
can be misleading. This may be particularly relevant when
the components of the composite outcome vary in clinical
importance. Studies demonstrate that the treatment effect
is often biggest for the less important components and
smallest for the most important component.11 This is con-
sistent with the present study in which the lower morbidity
components of the composite outcome (hepatic and renal
insufficiency and lactic acidosis) occurred more often
than any of the individual component event rates. The
studied composite outcome had an event rate of 39%,
which is closer to 50% than the most common individual
component, hepatic injury with a 22% event rate. Thus,
the use of this composite outcome will increase the power
of a study. The reduction in study population has the
advantages of reduced costs, ability to perform
investigations in a timely manner, and avoidance of an
arbitrary choice between several outcomes.

Despite the advantages of composite outcomes, their use
can be misleading. This may be particularly relevant when
the components of the composite outcome vary in clinical
importance. Studies demonstrate that the treatment effect
is often biggest for the less important components and
smallest for the most important component.11 This is con-
sistent with the present study in which the lower morbidity
components of the composite outcome (hepatic and renal
insufficiency and lactic acidosis) occurred more often
than any of the individual component event rates. The
studied composite outcome had an event rate of 39%,
which is closer to 50% than the most common individual
component, hepatic injury with a 22% event rate. Thus,
the use of this composite outcome will increase the power
of a study. The reduction in study population has the
advantages of reduced costs, ability to perform
investigations in a timely manner, and avoidance of an
arbitrary choice between several outcomes.

Despite the advantages of composite outcomes, their use
can be misleading. This may be particularly relevant when
the components of the composite outcome vary in clinical
importance. Studies demonstrate that the treatment effect
is often biggest for the less important components and
smallest for the most important component.11 This is con-
sistent with the present study in which the lower morbidity
components of the composite outcome (hepatic and renal
insufficiency and lactic acidosis) occurred more often
than any of the individual component event rates. The
studied composite outcome had an event rate of 39%,
which is closer to 50% than the most common individual
component, hepatic injury with a 22% event rate. Thus,
the use of this composite outcome will increase the power
of a study. The reduction in study population has the
advantages of reduced costs, ability to perform
investigations in a timely manner, and avoidance of an
arbitrary choice between several outcomes.
outcomes. However, our study was not sufficiently powered to determine the individual weight that should be applied to each component of the composite outcome.

**Study Limitations**

The components of the composite outcome and cutoffs for liver injury, renal injury, and lactic acidosis were based on previous reports, and each component was given equal weight. The best methods to define hepatic injury, renal injury, elevated lactic acidosis, and the weight of each component should be studied and would likely require a large multi-institutional network. With a larger study population, cutoff levels for each laboratory measure would have been based on statistical analysis instead of previously used levels, and each component could have been weighted given its relative associations with outcomes. Only neonates were studied, so the results may not be applicable to other populations. The proposed composite outcome may not be a useful marker in less complex populations. The composite outcome was only compared with 4 other early outcome measures, and the relationship to other early and late outcomes warrants further investigation.

**CONCLUSIONS**

The ideal composite outcome in clinical research would have a relatively high prevalence, be composed of clinically meaningful components that are weighted appropriately, and correlate with other short and long-term outcomes. A composite outcome consisting of death, CPR, ECMO, elevated lactate, and hepatic and renal injury is easily measured, reproducible, and highly associated with important early operative outcomes in neonates undergoing cardiac operations with CPB. The studied composite outcome had a high prevalence rate, and its components were selected using prior evidence. This composite outcome could serve as a useful end point for future clinical studies. Future studies should further refine the studied composite outcome and determine whether the composite outcome is associated with long-term outcomes.

**References**


24. Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Congenital Heart Disease: Volume 147, Number 1 433
